It is well established that recombinant human G-CSF accelerates neutrophil recovery following autologous peripheral blood stem cell transplantation (PBSCT). However, the optimal timing of G-CSF following transplantation remains unknown. We have conducted a retrospective analysis of patients treated with either early, day +1 (n = 42) or delayed, day +4 (n = 39) administration of G-CSF following autologous PBSCT for a variety of hematologic malignancies and solid tumors. G-CSF was given at a dose of 5 g/kg/day i.v. as a 2 h infusion beginning either day +1 or day +4 following PBSC infusion and continued until the total white blood count (WBC) was Ͼ10 × 10 9 /l. The numbers of transplanted CD34
logous PBSC transplantation 8, 9 the optimal timing of G-CSF administration post transplant is unknown.
Despite proven clinical benefit, early (day +1 or 0) treatment with G-CSF post transplant is an expensive therapeutic intervention. At a time of increasing demand for cost containment, delaying the start of G-CSF therapy for 4-7 days post infusion of stem cells may reduce transplant costs. However, compromising efficacy or jeopardizing the quality of patient care is a major concern.
Recombinant human G-CSF is a hematopoietic growth factor specific for neutrophil maturation. In kinetic studies, G-CSF amplifies the number of neutrophils, reduces the transit time to release of mature cells into the circulation, and enhances neutrophil function (increasing both neutrophil phagocytic candicidal and bactericidal activity) as well as survival. 10, 11 The primary effect of G-CSF has been shown to be on the late committed progenitors. Since both early and committed hematopoietic progenitors are more frequent in the mobilized PBSC population compared to bone marrow, 12, 13 using G-CSF early post PBSC transplant may provide an advantage in accelerating engraftment.
We have performed a retrospective analysis comparing the efficacy of early (day +1) administration of G-CSF 5 g/kg/day to delayed (day +4) administration following high-dose therapy and autologous PBSC support in a series of patients with hematologic malignancies and solid tumors.
Patients and methods

Patients
This study included 81 consecutive patients who underwent an autologous PBSCT for hematologic malignancy or solid tumor and who were treated with post-transplant G-CSF between January 1995 and March 1997. Eligibility criteria for transplantation included Karnofsky performance status of у70% and the absence of underlying organ dysfunction (for example, left ventricular ejection fraction Ͻ45% of predicted, serum creatinine Ͼ1.5 mg/ml or creatinine clearance Ͻ60 ml/min, serum bilirubin Ͼ2 mg/ml or transaminases Ͼtwo times normal), or significant hearing deficit (as determined by audiogram).
Detailed patient characteristics are shown in Table 1 . There were no statistically significant differences in patient or treatment characteristics between the two groups. The majority of patients in each arm were treated for breast cancer (52 vs 38%). Despite that, all Hodgkin's disease Ca = carcinoma; CY = cyclophosphamide; Carbo = carboplatin; TBI = total body irradiation; HD TBI = high-dose total body irradiation; BU = busulfan; ICE = ifosfamide, carboplatin and etoposide; Tax = taxol. patients were represented in the day +1 arm while a higher percentage of patients with non-Hodgkin's lymphoma (NHL) (23 vs 7.5%) were found in the day +4 arm. No statistically significant difference with respect to disease state was found (P = 0.07). The majority of patients in each treatment group received conditioning therapy with the CARBO/CY (carboplatin 600 mg/m 2 for 3 days and cyclophosphamide 2000 mg/m 2 for 3 days) regimen (71 vs 69%); a similar percentage of patients received a TBI containing regimen (12.3 vs 12.9%) (P = 0.60). Additionally, the cohorts did not differ with respect to prior treatment, number of relapses, or whether a complete or partial response had been achieved at the time of transplant. 
PBSC mobilization and collection
All patients received PBSC as their source of autologous stem cell support. PBSC were mobilized using either CY 
Administration of filgrastim
Patients received G-CSF (Neupogen; Amgen, Thousand Oaks, CA, USA) at a dose of 5 g/kg/day as a 2 h i.v. infusion, beginning either on day +1 in the first 47 patients or day +4 in the following 45 patients. G-CSF therapy was continued until the WBC remained above 10 × 10 9 /l. Engraftment was defined as the first of 3 consecutive days on which the neutrophil count was у0.5 × 10 9 /l.
Evaluation
The following clinical outcomes were evaluated: time to neutrophil recovery, length of hospitalization, number of infectious episodes and duration of i.v. antibiotics. Economic evaluation of hospital stay, G-CSF therapy, and NPA were based on costs at our institute. The cost of hospitalization was the product of the daily room cost in the bone marrow transplant unit of $1112 and the mean length of stay for each group. The cost of G-CSF (average dose of 400 g per day) and NPA (vancomycin 2 g and ceftazidime 3 g per day) were calculated based on the mean number of treatment days in each group.
Supportive care
All patients were treated in HEPA-filtered rooms. All patients received antimicrobial prophylaxis with an oral quinolone (ofloxacin 400 mg twice a day), fluconazole (400 mg load then 200 mg once daily), and acyclovir (400 mg orally or 5 mg/kg i.v. three times daily) from admission until the resolution of neutropenia. Trimethoprim-sulfamethoxazole was given for Pneumocytic carinii prophylaxis from admission until day −1, then resumed three times weekly following resolution of neutropenia until day 100 post-transplant. Emperic broad-spectrum i.v. antibiotic therapy usually with vancomycin 1 g twice a day and ceftazidime 1 g three times a day was initiated if a single temperature reading of greater than 38°C was recorded. Once initiated, intravenous antibiotics were continued until the patient was afebrile and neutrophil recovery occurred. Irradiated leukofiltered packed RBCs and platelets were transfused to maintain a hematocrit greater than 25% and a platelet count greater than 20 × 10 9 /l.
Statistical analysis
Statistical analysis was carried out using the Wilcoxon exact test, 14 Fisher exact test, or t-test as appropriate. Twosided P values Ͻ0.05 were considered statistically significant. Analysis of time to event (such as engraftment) were done using a Wilcoxon test, as these were not censored observations. Due to the small sample size all P values are from exact tests.
Results
Of the 47 patients treated with G-CSF starting on day +1, 42 are included in this analysis. In the day +4 group, 39 of 45 patients were evaluated. Although not statistically different from their respective groups, five patients from the day +1 group and six patients from the day +4 group were omitted from the analysis due to early hospital discharge. A comparison of the patient and treatment characteristics is presented in Table 1 . The cohorts were well balanced for age, sex, previous treatment, and status at transplant. Additionally, the treatment groups did not differ significantly with respect to disease state (P = 0.07) or conditioning regimen (P =0.60). Similar numbers of CD34 + cells were infused between the two groups.
Engraftment
All patients engrafted. As illustrated in Figure 1 , neutrophil engraftment was found to occur significantly more rapidly in the early treatment group compared to the delayed group (P Ͻ 0.0003). The time to reach an ANC greater than 0.5 × 10 9 /l was 8.5 days post-transplant among patients in the day +1 group and 10.0 days following transplant in the day +4 group (Table 2) . To determine if the shortened time Cumulative % of patients Days P < 0.0003 Figure 1 The number of days to reach an ANC of 0.5 × 10 9 /l in patients receiving G-CSF starting on day +1 (n = 42) (ۙ) or day +4 (n = 39) (J) following autologous PBSCT. to engraftment in the early treated group was associated with any patient characteristics other than the schedule of G-CSF administration, a Cox proportional hazards model was performed. The following variables were included into the base model: disease state, status, status at transplant, prior treatments, conditioning regimens, and number of CD34 + cells infused. The inclusion of any of the variables tested had no significant effect on engraftment.
A significantly longer duration of G-CSF treatment posttransplant was demonstrated in the day +1 group compared to the day +4 group (Table 2) , 10 days (range 7-19) vs 8.0 days (range 6-18), respectively (P = 0.007).
Hospitalization
A significant reduction in the median duration of post transplant hospitalization, 10 days vs 11 days (P = 0.0001), was observed between the early and delayed treatment groups ( Table 2 and Figure 2 ). The early administration of G-CSF was also associated with a significant reduction in the total length of stay (LOS) (16 days vs 17 days (P Ͻ 0.0008)) compared to the delayed treatment group.
Infections
A reduction in the number of patients who required nonprophylactic antibotics (NPA) therapy (53 vs 72%), P = 0.11) and in the median duration of NPA therapy 3 days (range 2-12) vs 5 days (range 2-13) was observed between the early and late treatment groups, respectively (P = 0.1) ( Table 3) . Since fever is a non-specific symptom and often an early complication of the CARBO/CY regimen, we evaluated the use of NPA in only those patients who were neutropenic (ANC Ͻ 0.5 × 10 9 /l) at the time of the recorded fever. Although a similar number of neutropenic patients required NPA in the day +1-treated group Table 3 Infectious complications compared to the day +4-treated group (13 vs 18) a significantly shorter duration of NPA therapy was required, 4.0 days (range 2-7) compared to 7.5 days (range 2-11), respectively (P Ͻ 0.009). Two documented infections were reported in the entire cohort; coagulase-negative Staphylococcus bacteremia was diagnosed in one patient from each group.
G-CSF
Economic analysis
Based on costs at our institution, a reduction in cost was associated with the early administration of G-CSF following autologous PBSC transplantation (Table 4) . Even with the added cost of 2 additional days of G-CSF dosing in the day +1 group, an overall cost saving of $2325 per transplant was observed due to shortened hospital stays (shortened inpatient stay reduced the cost per patient by $2557) and reduced antibiotic requirements.
Discussion
This retrospective analysis has shown that early post-transplant (day +1) administration of G-CSF is associated with a significantly shorter time to neutrophil engraftment, decreased length of hospitalization, and reduced antibiotic requirements for patients with neutropenic fever compared to delayed (day +4) administration. Several studies have evaluated the efficacy of delayed G-CSF compared to no treatment following autologous bone marrow (ABMT) 15, 16 or PBSC transplantation. 17 In a retrospective study, Dunlop and colleagues 17 compared the delayed administration of 10 g/kg/day of G-CSF following autologous PBSCT (± BMT) on day +5 (n = 10) with no treatment (n = 9). Interestingly, no beneficial differences were observed in the day of engraftment, incidence of fever, antibiotic use, or day of discharge with delayed administration (day +5) of G-CSF over the non-treated arm. However, in other studies evaluating day +1 G-CSF vs no treatment, early use of growth factor improved clinical outcome. 4, 5 Klumpp and colleagues in a prospective randomized trial of day +1 vs no G-CSF therapy following autologous PBSCT, demonstrated Table 4 Cost analysis Expected cost savings $2325 per transplant LOS = length of stay; costs of hospital stay based on $1112/day in the BMT unit; cost of G-CSF based on an average dose of 400 g/day; antibiotic costs based on the addition of vancomycin 2 g and ceftazidime 3 g/day. a Statistically significant (P Ͻ 0.0008) a significant reduction in the time to engraftment, hospital stay, and NPA requirements. 4 Madero and colleagues 5 evaluated day +1 G-CSF following autologous BMT in pediatric patients with hematologic malignancies compared to a similar non-treated historical control group. Administration of G-CSF led to a faster neutrophil recovery, fewer febrile days, and a decrease in antibiotic use. Thus, in agreement with our findings, early treatment with G-CSF following autologous PBSCT provides a beneficial clinical outcome compared with delayed administration of G-CSF or no treatment at all. Two studies have evaluated the use of delayed post-ABMT G-CSF compared to day +1 administration. 18, 19 In a retrospective study by Vey and colleagues, 18 administration of G-CSF 5 g/kg/day as a 30 min i.v. infusion on day +1 (n = 24) was compared to day +6 administration (n = 25) following ABMT. No difference was observed in the time to engraftment, length of hospitalization, or infectious complications. Torres and colleagues, 19 in a prospective randomized study, compared G-CSF 5 g/kg/day administered as a 30 min i.v. infusion on day 0 (n = 11) with day +7 administration (n = 11) following ABMT. No significant difference in the time to neutrophil recovery was reported between the two groups.
The results of these two studies which evaluated the effect of timing of G-CSF administration on clinical outcome are in contrast to our experience. In addition to their small sample size, bone marrow cells (BMC) were utilized as the source of stem cell reconstitution. The rapidity of hematologic recovery following PBSC compared to BM transplants makes a direct comparison with our study difficult. Quantitative differences in the subpopulations of mobilized peripheral stem cells from that of harvested bone marrow have been demonstrated. 13 Cytokine-mobilized peripheral stem cells contain greater numbers of late committed progenitors which may be directly stimulated by early administered exogenous G-CSF, thus limiting a comparison of our results with studies evaluating the engraftment characteristics of BMT.
Although this study demonstrates a significant advantage of early vs delayed G-CSF following autologous PBSCT, it is limited by its retrospective study design. One could argue that the shorter time to recovery, early discharge and reduced NPA requirements are not solely due to the early administration of G-CSF therapy. However, our study populations were shown to be similar both in prior treatment and clinical characteristics. In addition, applying a Cox proportional hazard model did not identify any variable significantly associated with the time of engraftment in either cohort. Thus, the beneficial effects demonstrated in this study may be due primarily to the schedule of G-CSF therapy.
In a recent prospective randomized study of patients undergoing transplantation for HD, NHL and MM, Cetkovsky and colleagues, 20 compared G-CSF 10 g/kg/day, administration as a fixed continuous infusion on day +1 following PBSCT (n = 43) to a delayed patient-dependent administration (n = 42) (dosed on first day the ANC fell below 0.5 × 10 9 /l). No differences were reported in either time to engraftment or duration of post-transplant hospitalization between the two treated groups, 12 vs 13 days and 22 vs 24 days, respectively. Due to the sliding-scale approach of the delayed G-CSF administration, identification of a significant difference may have been obscured between the two dosing schedules. In addition, it would suggest, that since the time to engraftment and day of discharge in our study were substantially earlier in patients with similar diseases states, other factors or patient parameters may be responsible for the non-significant findings.
Much of the morbidity associated with autologous transplantation is dependent on the duration of neutropenia. In our study a significantly earlier engraftment in the day +1 G-CSF treatment group was associated with an earlier discharge from hospital. This was evident both in the duration of hospitalization following PBSCT and total length of stay. The incidence of fever was not significantly different between the treatment groups. However, fever is a nonspecific symptom and may be related to the conditioning regimen, a drug reaction, or engraftment. We recognize that the CARBO/CY conditioning regimen is associated with fevers at the time of infusion, thus patients in both treatment arms would have been equally likely to have NPA initiated. Since development of neutropenic fever is a clinically significant end-point in this population, we analyzed only those patients who were neutropenic at the time of the reported fever. A non-significant reduction in the incidence of fever was observed in neutropenic patients treated on day +1. However, there was a significant reduction in the mean duration of NPA (4.0 days vs 7.5 days) in the day +1 and day +4 groups, respectively. This decrease in NPA treatment may reflect a shortened time of neutropenia and earlier time to engraftment seen in the day +1 group. It is possible that our population was not large enough to fully evaluate the beneficial effects of early G-CSF administration on the incidence of fever and antibiotic requirements.
The reduction in the number of days of neutropenia also resulted in a reduction in both direct and secondary costs associated with autologous PBSC transplantation. Cost estimates in this study suggest an overall saving of about 11% per transplant with the early administration of G-CSF following transplantation. The additional cost for G-CSF in the day +1-treated group was offset by cost savings associated with early discharge and reduced antibiotic requirements. This value may actually under-represent the true savings associated with early G-CSF administration as it does not reflect the cost associated with continued laboratory monitoring as well as ancillary drug costs associated with a more prolonged hospitalization.
In summary, early post-transplant administration of G-CSF was found to enhance neutrophil recovery, shorten hospital stay, and reduce antibiotic requirements for patients undergoing PBSCT for hematologic malignancy or solid tumors. Despite the increase in cost of G-CSF, the beneficial effects associated with early G-CSF administration resulted in an overall cost saving. However, in the light of the retrospective study design, the clinical and economic outcomes reported here warrant further evaluation in a prospective randomized study.
